Advertisement
Advertisement
DYN
Dyne Therapeutics, Inc. Common Stock
26.25
USDSponsored
+0.37
+1.43%
Aug 07, 15:59 UTC -4
Closed
After-Market
26.08
-0.17
-0.65%
DYN Earnings Reports
Positive Surprise Ratio
DYN beat 9 of 24 last estimates.
38%
Next Report
Date of Next Report
Nov 02, 2026
Estimate for Q3 26 (Revenue/ EPS)
--
/-$0.78
Implied change from Q2 26 (Revenue/ EPS)
--
/-27.78%
Implied change from Q3 25 (Revenue/ EPS)
--
/+2.63%
Dyne Therapeutics, Inc. Common Stock earnings per share and revenue
On Jul 29, 2026, DYN reported earnings of -1.08 USD per share (EPS) for Q2 26, missing the estimate of -0.75 USD, resulting in a -42.44% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +2.51% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 9 analysts forecast an EPS of -0.78 USD, with revenue projected to reach -- USD, implying an decrease of -27.78% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Definium Therapeutics, Inc. Common Shares
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.55
Actual
-$1.44
Surprise
-158.25%
Relay Therapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.39
Actual
-$0.41
Surprise
-2.78%
Amylyx Pharmaceuticals, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.36
Actual
-$0.39
Surprise
-5.95%
Ardelyx, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.05
Actual
-$0.07
Surprise
-18.85%
Collegium Pharmaceutical, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
$1.74
Actual
$1.92
Surprise
+9.75%
Cronos Group Inc. Common Share
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.00
Actual
$0.03
Surprise
0.00%
Relmada Therapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.20
Actual
-$0.11
Surprise
+45.95%
Organogenesis Holdings Inc. Class A Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.35
Actual
-$0.71
Surprise
-98.88%
Profound Medical Corp. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.26
Actual
$0.26
Surprise
+199.01%
OmniAb, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.12
Actual
-$0.05
Surprise
+59.15%
FAQ
What were Dyne Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Dyne Therapeutics, Inc. Common Stock reported EPS of -$1.08, missing estimates by -42.44%, and revenue of $0.00, 0% as expectations.
How did the market react to Dyne Therapeutics, Inc. Common Stock's Q2 2026 earnings?
The stock price moved up 2.51%, changed from $25.10 before the earnings release to $25.73 the day after.
When is Dyne Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Nov 02, 2026.
What are the forecasts for Dyne Therapeutics, Inc. Common Stock's next earnings report?
Based on 9
analysts, Dyne Therapeutics, Inc. Common Stock is expected to report EPS of -$0.78 and revenue of -- for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement